Conference call to discuss details on the asthma opportunity for briquilimab will be held on May 20 at 8 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics reports Q1 EPS ($1.03), consensus ($1.22)
- Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
- Jasper Therapeutics announces briquilimab development program in asthma
- Jasper Therapeutics Announces Briquilimab Development Program in Asthma
- JSPR Earnings this Week: How Will it Perform?